- TOUCH On-Line
The TOUCH Prescribing Program is designed to: Inform prescribers, infusion center healthcare providers, and patients about the risk of progressive multifocal leukoencephalopathy (PML) associated with TYSABRI including the increased risk of PML with treatment duration and prior immunosuppressant use
- TOUCH On-Line
Prescribers, infusion sites, certified pharmacies associated with infusion sites and patients must all enroll in the TOUCH Prescribing Program in order to prescribe, infuse, dispense or receive TYSABRI
- Overview of the TOUCH Program
Prescribers, infusion sites, certified pharmacies and patients must all enroll in the TOUCH Prescribing Program in order to prescribe, infuse, dispense, or receive TYSABRI
- TOUCH On-Line
TOUCH Prescribing Program Educational Slide Set Presentation to provide education necessary to execute TOUCH Prescribing Program, intended for prescribers, infusion sites, and certified pharmacies
- PowerPoint Presentation
The TOUCH Prescribing Program will track all patients over time, so that Biogen can inform the FDA, prescribers, and patients in a timely manner of information regarding the safety of TYSABRI®
- Please see the Prescribing Information, including BOXED WARNING,
The TOUCH Prescribing Program makes TYSABRI® available only to prescribers, infusion sites, pharmacies associated with infusion sites, and patients who are enrolled in the program
- Helpful information for evaluation of new neurological symptoms in . . .
To that end, Biogen, in conjunction with the Food and Drug Administration (FDA), developed a risk management plan for the United States called the TOUCH® Prescribing Program
- Para obtener más información, llama al Guía del Medicame
Informa a todos tus médicos que estás recibiendo un tratamiento con TYSABRI Debido a tu riesgo de contraer LMP mientras recibes un tratamiento con TYSABRI, TYSABRI está disponible únicamente a través de un programa de distribución con restricciones llamado Programa de Prescripción TOUCH®
|